Breast Cancer, HER2 Clinical Trial
Official title:
HER2 Retrospective Epidemiology Study Prevalence and Clinicopathologic Features of Different HER2 Level in Chinese Breast Cancer Patients (HER2 PATH)
This retrospective study aims to describe the prevalence and clinical manifestations of different HER2 level BC by accurate reassessing of HER2 expression in archived HER2 IHC slides, and analysing clinicopathologic feature and outcomes from Fudan University Shanghai Cancer Centre (FUSCC) Breast Cancer Single Disease Database
This is a single-centre, retrospective study to describe the prevalence of different HER2 expression levels (HER2-high, HER2-low, HER2 Ø) in approximately 3000 breast cancer patients at FUSCC through the year of 2015. This study will collect re-assessed HER2 expression level results based on the archived HER2 IHC slides while relative demographic, treatment, clinicopathologic and efficacy data will be extracted from the FUSCC Breast Cancer Single Disease Database. ;
| NCT number | NCT05203458 |
| Study type | Observational |
| Source | AstraZeneca |
| Contact | AstraZeneca Clinical Study Information Center |
| Phone | 1-877-240-9479 |
| [email protected] | |
| Status | Recruiting |
| Phase | |
| Start date | February 24, 2022 |
| Completion date | May 31, 2022 |